Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Decreased plasma levels of the survival factor renalase are associated with worse outcomes in COVID-19

Melinda Wang, Xiaojia Guo, Hyung J Chun, Alfred Ian Lee, Charles Cha, Fred Gorelick, Gary V Desir
doi: https://doi.org/10.1101/2020.06.02.20120865
Melinda Wang
1Department of Medicine, New Haven, CT and VA CT Health Care, West Haven, CT
4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaojia Guo
1Department of Medicine, New Haven, CT and VA CT Health Care, West Haven, CT
4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyung J Chun
1Department of Medicine, New Haven, CT and VA CT Health Care, West Haven, CT
4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Ian Lee
1Department of Medicine, New Haven, CT and VA CT Health Care, West Haven, CT
4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Cha
2Department of Surgery, New Haven, CT and VA CT Health Care, West Haven, CT
4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Gorelick
1Department of Medicine, New Haven, CT and VA CT Health Care, West Haven, CT
3Department of Cell Biology, New Haven, CT and VA CT Health Care, West Haven, CT
4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gary.desir@yale.edu
Gary V Desir
1Department of Medicine, New Haven, CT and VA CT Health Care, West Haven, CT
4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Renalase (RNLS), a novel secreted plasma flavoprotein, has anti-inflammatory effects in a variety of disease processes. Severe COVID-19 disease is associated with disordered inflammatory responses. We hypothesized that reduced plasma RNLS levels could be a marker of COVID-19 disease severity.

Methods Plasma was collected from 51 hospitalized COVID-19 patients and 15 uninfected non-hospitalized controls. Plasma RNLS and cytokine levels were measured and sociodemographic and clinical data were collected from chart review. Data were analyzed using nonparametric analyses and Kaplan Meir curve log rank analysis.

Results Plasma RNLs levels were negatively correlated with inflammatory markers, including IL-1β, IL- 6, and TNFα (p = 0.04, p = 0.03, p = 0.01, respectively). Patients with COVID-19 disease had lower levels of RNLS than controls. Lower levels of RNLS were associated with more severe disease among COVID-19 patients. Low RNLS was also associated with worse survival among COVID-19 patients (HR = 4.54; 95% Cl: 1.06–19.43; p = 0.005).

Conclusion Low plasma RNLS levels are associated with severe COVID-19 disease and may be a useful additional biomarker when identifying patients with severe COVID-19 disease. Given RNLS’ antiinflammatory properties and negative correlation with inflammatory markers, these findings also suggest evidence of a potential pathophysiological mechanism for severe COVID-19 disease.

Competing Interest Statement

G V Desir is a named inventor on several issued patents related to the discovery and therapeutic use of renalase. Renalase is licensed to Bessor Pharma, and G V Desir holds an equity position in Bessor and its subsidiary Personal Therapeutics.

Funding Statement

This work was supported in part by the National Institute of Health grants DK098108 (F Gorelick), R44 DK111251 (G V Desir, F Gorelick), and DK007017 (M Wang); VA Merit Award (F Gorelick, G V Desir); Department of Defense Cancer Award (F Gorelick, G V Desir)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol was approved by the Yale University institutional review board (HIC 2000027792).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data referred to in this manuscript are not currently available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Decreased plasma levels of the survival factor renalase are associated with worse outcomes in COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Decreased plasma levels of the survival factor renalase are associated with worse outcomes in COVID-19
Melinda Wang, Xiaojia Guo, Hyung J Chun, Alfred Ian Lee, Charles Cha, Fred Gorelick, Gary V Desir
medRxiv 2020.06.02.20120865; doi: https://doi.org/10.1101/2020.06.02.20120865
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Decreased plasma levels of the survival factor renalase are associated with worse outcomes in COVID-19
Melinda Wang, Xiaojia Guo, Hyung J Chun, Alfred Ian Lee, Charles Cha, Fred Gorelick, Gary V Desir
medRxiv 2020.06.02.20120865; doi: https://doi.org/10.1101/2020.06.02.20120865

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1774)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10826)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2963)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1935)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (294)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12530)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2815)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (258)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (340)
  • Psychiatry and Clinical Psychology (2650)
  • Public and Global Health (5387)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (293)
  • Sports Medicine (279)
  • Surgery (328)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (127)